BioXcel Therapeutics, Inc.
BTAI
$4.98
-$0.25-4.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -28.57% | -54.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -28.57% | -54.10% | |||
| Cost of Revenue | 664.29% | -98.32% | |||
| Gross Profit | -91.56% | 133.05% | |||
| SG&A Expenses | -1.58% | 39.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 55.57% | -5.17% | |||
| Operating Income | -56.97% | 3.46% | |||
| Income Before Tax | -164.50% | 33.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -164.50% | 33.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -164.50% | 33.20% | |||
| EBIT | -56.97% | 3.46% | |||
| EBITDA | -57.41% | 3.48% | |||
| EPS Basic | -63.03% | 58.00% | |||
| Normalized Basic EPS | -63.02% | 57.88% | |||
| EPS Diluted | -63.03% | 58.00% | |||
| Normalized Diluted EPS | -63.02% | 57.88% | |||
| Average Basic Shares Outstanding | 62.25% | 59.07% | |||
| Average Diluted Shares Outstanding | 62.25% | 59.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||